Article Text

Download PDFPDF

934 Mechanisms of immune escape in NF1-associated peripheral nerve sheath tumors
  1. Lindy Zhang1,
  2. Alexandre Maalouf1,2,3,
  3. Ana Calizo1,
  4. Aditya Suru1,2,3,
  5. Stavriani Makri1,3,
  6. Jineta Banerjee4,
  7. John Gross1,3,
  8. Christine Pratilas1,3 and
  9. Nicolas Llosa1,2,3
  1. 1Johns Hopkins University School of Medicine, Baltimore, MD, USA
  2. 2Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, USA
  3. 3Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
  4. 4Sage Bionetworks, Seattle, WA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Neurofibromatosis type 1 (NF1) is a neurogenetic condition with stereotypic cutaneous findings and a predisposition for benign and malignant tumors. About half of patients will develop plexiform neurofibromas (PN), non-malignant tumors that have a 10% lifetime risk of developing into aggressive soft tissue sarcomas called malignant peripheral nerve sheath tumors (MPNST). Some lesions, denoted atypical neurofibromatous neoplasms of uncertain biologic potential (ANNUBP), exhibit histopathologic features and are precursors to MPNST. Despite many clinical trials, there has been little advancement in treatment outcomes and overall survival remains poor; therefore, new therapeutic approaches are needed. PNST are composed of transformed Schwann cell precursors that interact with infiltrating immune cells. An understanding of the relationship between the pre-existing immunity and tumor microenvironment (TME) will help unveil potential for immunotherapeutics.

Methods We used complementary techniques to interrogate the TME in NF1-associated PNST. 15 pNF, 8 ANNUBP, and 18 MPNST specimens were analyzed to compare the quantitative and spatial resolution of the geography and nature of tumor infiltrating immune cells during progression to malignancy. We determined the interactions of immune cells and immunoregulatory molecules, using a combination of multiplex flow cytometry (MFC) and gene expression profiling studies. Lastly, we correlated these findings with clinical outcomes.

Results Immunophenotyping confirmed the higher presence of infiltrating myeloid compared to lymphoid cells, with a predominance of CD163+ myeloid cells during malignant transformation. Similarly, transcriptomic data showed significant accumulation of immunosuppressive myeloid populations in MPNST. The MPNST TME was consistent with an immune excluded phenotype on spatial resolution. MFC further characterized CD163+ myeloid cells as immunosuppressive with a high PD-L1 expression. Higher expression of CD8+ T cells and lower PD-L1 in MPNST correlated with improved survival.

Conclusions An immunosuppressive microenvironment characterizes PNST during the process to malignancy, generating an immune-excluded phenotype. This progression of pre-malignant tumors to malignancies can respond to the principles of immunoediting; thus, we believe that immunotherapies may be a therapeutic option in patients with MPST. Further studies on PD-L1 expression may reveal it as a useful biomarker. The mechanisms of immune modulation in PNST will inform interventions to stimulate anti-tumor immunity in this disease.

Acknowledgements This research has been funded by the Children’s Tumor Foundation, Children’s Cancer Foundation, Neurofibromatosis Therapeutic Acceleration Program.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.